Garg et al. report that blocking the molecule SEMA4D strengthens immune responses against HER2-positive breast cancer. When paired with specialized dendritic cells, this approach boosts anti-tumor immune activity, reduces suppressive cells, and enables clearance of both local and distant tumors. Their findings support a promising and well-tolerated immunotherapy strategy.